Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$1.75
+0.6%
$1.35
$1.05
$8.79
$117.58M-0.11488,586 shs685,709 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$8.75
+29.8%
$7.12
$4.58
$9.66
$337.92M1.88443,872 shs9.68 million shs
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$10.11
$10.11
$4.80
$18.13
$386.95M1.491.58 million shs1.07 million shs
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
$8.05
$7.98
$1.31
$8.10
$383.91M3.331.09 million shsN/A
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Climb Bio, Inc. stock logo
CLYM
Climb Bio
+0.57%+15.13%+38.89%+44.63%+174,999,900.00%
CryoPort, Inc. stock logo
CYRX
CryoPort
+29.82%+16.05%+20.03%+25.27%+12.32%
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
0.00%-0.10%+0.40%+50.78%-35.23%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-0.25%0.00%+0.75%+231.96%+117.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Climb Bio, Inc. stock logo
CLYM
Climb Bio
2.714 of 5 stars
3.60.00.00.01.12.51.3
CryoPort, Inc. stock logo
CYRX
CryoPort
3.4357 of 5 stars
4.42.00.00.01.62.51.3
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
2.7559 of 5 stars
4.12.00.00.00.33.30.6
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
3.1065 of 5 stars
4.03.00.00.01.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3.25
Buy$9.00414.29% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.89
Moderate Buy$12.0037.14% Upside
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
2.14
Hold$15.6454.73% Upside
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
2.00
Hold$10.8034.16% Upside

Current Analyst Ratings Breakdown

Latest CLYM, CYRX, ITOS, and VIGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Weight ➝ Overweight$15.00
8/6/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$16.00
7/22/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$13.00
7/21/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/21/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$12.00 ➝ $10.50
7/7/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $10.00
6/6/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$10.00
5/28/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.00
5/28/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$10.00 ➝ $12.00
5/28/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$11.00 ➝ $8.00
5/27/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$14.00 ➝ $8.00
(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/A$3.15 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.92N/AN/A$7.44 per share1.18
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$35M11.05N/AN/A$16.16 per share0.63
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/A$1.75 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$73.90M-$2.38N/AN/AN/AN/A-43.95%-42.94%8/13/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M$1.336.58N/AN/A37.21%-10.48%-5.56%N/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$134.41M-$3.04N/AN/AN/AN/A-21.37%-18.55%8/14/2025 (Estimated)
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$84.26M-$2.05N/AN/AN/AN/A-111.70%-74.67%8/12/2025 (Estimated)

Latest CLYM, CYRX, ITOS, and VIGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$0.94N/AN/AN/AN/AN/A
8/13/2025Q2 2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$0.19N/AN/AN/AN/AN/A
8/6/2025Q2 2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$1.12-$1.51-$0.39-$1.81N/AN/A
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.29-$0.09$2.05$41.74 million$45.45 million
5/14/2025Q1 2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$0.15-$0.31-$0.16-$0.31N/AN/A
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
5/7/2025Q1 2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$0.53-$0.49+$0.04-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/AN/AN/AN/AN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/A
14.25
14.25
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/A
14.13
14.13
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/A
2.97
2.97

Institutional Ownership

CompanyInstitutional Ownership
Climb Bio, Inc. stock logo
CLYM
Climb Bio
69.76%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
97.16%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
83.64%

Insider Ownership

CompanyInsider Ownership
Climb Bio, Inc. stock logo
CLYM
Climb Bio
0.80%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
12.50%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
18.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Climb Bio, Inc. stock logo
CLYM
Climb Bio
967.58 million67.04 millionN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.12 millionOptionable
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
9038.27 million33.49 millionOptionable
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
4047.69 million39.10 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Climb Bio stock logo

Climb Bio NASDAQ:CLYM

$1.75 +0.01 (+0.57%)
As of 08/6/2025 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$8.75 +2.01 (+29.82%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$8.91 +0.16 (+1.89%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

iTeos Therapeutics stock logo

iTeos Therapeutics NASDAQ:ITOS

$10.11 0.00 (0.00%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$10.30 +0.19 (+1.83%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Vigil Neuroscience stock logo

Vigil Neuroscience NASDAQ:VIGL

$8.05 0.00 (0.00%)
As of 08/5/2025

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.